Alnylam agreed a multi-year, potentially $2 billion AI collaboration with Inceptive Nucleics to accelerate discovery of RNA interference therapies. The agreement includes $30 million upfront and milestone payments tied to preclinical, regulatory, and commercial outcomes, positioning AI as a catalyst for target selection and experimental productivity. The partnership leverages Inceptive’s foundation-model approach designed for sequence-based medicines, with early exploratory work reporting rapid performance in characterizing small interfering RNA molecules. The deal adds to a growing pattern of pharma adopting model-based workflows to shrink iteration cycles. Separately, Sophia Genetics also moved to scale precision medicine by planning a hub with Memorial Sloan Kettering Cancer Center (MSK) combining Sophia’s DDM AI platform and MSK’s clinical data infrastructure for translational oncology and companion diagnostic development.